Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference43 articles.
1. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28;Mamounas;J Clin Oncol,2005
2. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer;Henderson;J Clin Oncol,2003
3. Weekly paclitaxel in the adjuvant treatment of breast cancer;Sparano;N Engl J Med,2008
4. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology research trial 9735;Jones;J Clin Oncol,2009
5. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial;Mackey;Lancet Oncol,2013
Cited by 52 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The novel combination of mocetinostat and capecitabine has a greater anti-tumoral effect on induced breast cancer in BALB/c mice;2024-05-21
2. Catalysts of Healing: A Symphony of Synthesis and Clinical Artistry in Small-Molecule Agents for Breast Cancer Alleviation;Molecules;2024-03-05
3. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer;Biologics: Targets and Therapy;2023-09
4. PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer;Cell Death & Disease;2023-04-18
5. A Predictive Model for the Early Death of Breast Cancer With Synchronous Liver Metastases: A Population-Based Study;Cancer Control;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3